SALT LAKE CITY and BOSTON — Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage Myriad’s advanced laboratory capabilities in the […]

BOSTON — SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & CDx Summit in Boston. The companies aim to improve the diagnosis and treatment of breast and prostate cancer by developing an optimized next generation sequencing (NGS) solution that leverages SOPHiA GENETICS’s AI […]

Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of ‘gene silencing’ medicines Members leverage AI-powered dataset to accelerate pharma R&D, andensure that disease-impacting discoveries benefit all people SAN DIEGO — Illumina, Inc. (NASDAQ: ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) (Alnylam) as […]

The new co-marketing and distribution partnership enables SureSeq™ NGS panel customers to purchase QIAGEN’s tertiary analysis software QIAGEN Clinical Insight (QCI®) Interpret as part of a complete SureSeq NGS workflow solution, unlocking comprehensive analysis from sample to report QIAGEN Digital Insights bioinformatics bring over 25 years of expertise in expert-curated content, AI-powered proprietary algorithms and […]

Synthesize Bio’s generative genomics models predict the results of gene expression experiments with unprecedented accuracy Funding led by Madrona with participation from AI2 Incubator, Sahsen Ventures, Inner Loop Capital and Point Field Partners Synthesize Bio is actively engaging with biopharma partners to enable more confident drug development decisions using generative genomics GEM-1 foundation model now […]

Oxford Nanopore Technologies, the company behind a new generation of molecular sensing technology based on nanopores, has announced the launch of its Microbial Amplicon Barcoding Kit 24 V14, to enable faster and more flexible microbial analysis in a single workflow. Oxford Nanopore’s new kit has been optimised to provide an information-rich, rapid, and accessible full-length amplicon […]

RiboMarker-NextGen Biomarker Discovery SANTA CRUZ, CA, UNITED STATES — RealSeq Biosciences, a pioneer in RNA-based diagnostics, today announced it has received a Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) (FAIN# R44HG013284; Federal Award Date: August 15, 2025). This highly competitive award provides multi-year, non-dilutive funding to accelerate […]

New formats redefine molecular assay development by cutting refrigeration costs, simplifying logistics, and ensuring uncompromised performance at room temperature. CINCINNATI — The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, today announced the launch of the industry’s first liquid qPCR master mixes proven stable for over […]

San Diego, CA – Genesee Scientific, a leading provider of high-quality, value-driven lab essentials, today announced the acquisition of Jade Scientific, a Michigan-based distributor recognized for its extensive offering of chemicals and consumables to clinical reference, pharma/biotech, and environmental labs nationwide. This strategic acquisition marks a significant milestone in Genesee’s growth journey. Together, the two companies will […]

Researchers aim to identify cellular circuit mechanisms and generate a dataset to fuel AI-driven foundational research of lung biology MUNICH, Germany and SEATTLE, United States — Helmholtz Munich and Parse Biosciences today announced a strategic partnership to generate the world’s broadest lung disease perturbation atlas, powered by Parse Biosciences’ GigaLab platform. Using a human lung ex-vivo tissue […]